Decorative image

Research

Tests of treatments on patients are called clinical trials. Cancer Research UK supports many UK and international clinical trials. The video shows what it is like to take part in a trial.

Research into scans for head and neck cancers

Researchers are looking at ways of improving scans to diagnose cancer and also to see how well treatment is working.

Research into treatments

Researchers are looking at ways of improving treatments, including radiotherapy, chemotherapy, and targeted cancer drugs.

Talk to your healthcare team to find out if there are any trials that you might be able to take part in.

Research into immunotherapy and a targeted cancer drug

Pembrolizumab is an immunotherapy Open a glossary item. It works by stimulating your immune system to help fight cancer. Doctors use pembrolizumab to treat cancer including some head and neck cancers.

Lenvatinib is a targeted drug Open a glossary item called a cancer growth blocker. It works by blocking signals that tell cancer cells to grow. Doctors use lenvatinib to treat some cancers but not head and neck cancers. 

Researchers are looking at whether having lenvatinib with pembrolizumab works better than pembrolizumab on its own as a treatment for head and neck cancer. 

Oxygen treatment to prevent bone damage

Sometimes radiotherapy to the head and neck area can damage the jawbone. This damage is called osteoradionecrosis (ORN). If the damage is bad enough to cause symptoms, you might need surgery to remove the damaged part of the jawbone.

A research study looked at whether a treatment called hyperbaric oxygen could help to heal the jaw bone after surgery. We are waiting to see what the results of this study will show. 

Research into the long term side effects of radiotherapy

A study is looking into developing a computer tool to predict what long term side effects people might have after radiotherapy.

Search for a trial

You can go to our clinical trials database and look for clinical trials for nasal and paranasal sinus cancer.